Parameters | Mean | SE | Distribution | Source |
---|---|---|---|---|

Survival probabilities per year | ||||

Ipilimumab | ||||

PFS | 0.175 | 0.012 | Beta | [6] |

OS | 0.366 | 0.018 | Beta | [6] |

TIL | ||||

PFS | 0.234 |
0.089^{a}
| Beta | [10, 11] |

OS | 0.412 |
0.098^{a}
| Beta | [10, 11] |

Utilities and side effects | ||||

Ipilimumab | ||||

Stable disease | 0.850 | 0.020 | Beta | [18] |

Progression | 0.590 | 0.020 | Beta | [18] |

TIL | ||||

Stable disease | 0.850 | 0.020 | Beta | [18] |

Progression | 0.590 | 0.020 | Beta | [18] |

Utility decrements | ||||

Fatigue | 0.090 | 0.020 | Beta | [18] |

Diarrhea | 0.060 | 0.020 | Beta | [18] |

Colitis | 0.130 | 0.020 | Beta | [18] |

Neutropenia | 0.130 | 0.020 | Beta | [18] |

Dyspnea | 0.100 | 0.020 | Beta | [18] |

Flu-like syndrome (grade I/II)) | 0.090 | 0.020 | Beta | [18] |

Anaemia | 0.110 | 0.020 | Beta | [18] |

Likelihood of side effects | ||||

Ipilimumab | ||||

Fatigue | 0.070 | 0.015 | Beta | [6] |

Diarrhea | 0.060 | 0.015 | Beta | [6] |

Colitis | 0.060 | 0.015 | Beta | [6] |

Dyspnea | 0.040 | 0.015 | Beta | [6] |

Immune | 0.100 | 0.015 | Beta | [6] |

Anaemia | 0.030 | 0.015 | Beta | [6] |

TIL^{a}
| ||||

Fatigue | 0.001 | 0.001 | Beta | [24] |

Diarrhea | 0.001 | 0.001 | Beta | [24] |

Neutropenia | 0.560 | 0.100 | Beta | [24] |

Dyspnea | 0.020 | 0.015 | Beta | [24] |

Immune | 0.220 | 0.100 | Beta | [24] |

Anaemia | 0.440 | 0.100 | Beta | [24] |

Failures, non-compliance TIL | ||||

Failures | 0.100 | 0.015 | Beta | [20], Expert opinion |

Non-compliance | 0.100 | 0.015 | Beta | [21] |

Costs in euros | ||||

Costs of ipilimumab total | 91,487.50 | +/-25% | Gamma | |

Drug | 90,100.00 | +/-25% | Gamma | [22] |

Administration | 473.00 | +/-25% | Gamma | [23] |

Management of side effects | 914.50 | +/-25% | Gamma | [6, 16] |

Costs of TIL total | 62,000.00 | +/-25% | Gamma | NKI-AVL |

TIL-production-total^{b}
| 35,500.00 | +/-25% | Gamma | NKI-AVL |

Personnel | 18,000.00 | +/-25% | Gamma | NKI-AVL |

Material and quality control | 10,000.00 | +/-25% | Gamma | NKI-AVL |

Cleanroom and equipment | 7,500.00 | +/-25% | Gamma | NKI-AVL |

TIL-hospital-total | 26,500.00 | +/-25% | Gamma | NKI-AVL |

admission | 13,000.00 | +/-25% | Gamma | NKI-AVL |

Preparatory surgery | 6,500.00 | +/-25% | Gamma | NKI-AVL |

Side-effects, medication, monitoring | 6,500.00 | +/-25% | Gamma | NKI-AVL |

Costs of follow-up stable disease^{c}
| 516.00 | +/-25% | Gamma | [25] |

Costs progressive disease^{d}
| 9,125.00 | +/-25% | Gamma | [31] |

Costs of side effects for ipilimumab | ||||

Fatigue | 198.00 | +/-25% | Gamma | [16] |

Diarrhea | 580.00 | +/-25% | Gamma | [16] |

Colitis/neutropenia^{e}
| 1115.00 | +/-25% | Gamma | [16] |

Dyspnea | 100.00 | +/-25% | Gamma | Assumption |

Immune | 7,680.00 | +/-25% | Gamma | [16] |

Anaemia | 898.00 | +/-25% | Gamma | [16] |